Biomarkers for prediction of TNFα blockers response in rheumatoid arthritis

Joint Bone Spine

Volumn 77, Issue 4, 2010, Pages 297-305

  Marotte, Hubert ^a   Miossec, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Predictive biomarker; Rheumatoid arthritis; TNF blocker

Indexed keywords

ADALIMUMAB; ANTIPERINUCLEAR FACTOR; AZATHIOPRINE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CPH 82; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; ETANERCEPT; FC RECEPTOR IIA; GAMMA INTERFERON; GLUCOSE 6 PHOSPHATE ISOMERASE; GOLD SALT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MICROSATELLITE DNA; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

BLOOD; COHORT ANALYSIS; DEMOGRAPHY; DRUG COST; DRUG EFFICACY; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; JOINT BIOPSY; PREDICTION; PROGNOSIS; PROTEOMICS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SYNOVIUM; TREATMENT RESPONSE; DRUG ANTAGONISM; GENETICS; PREDICTION AND FORECASTING; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; HUMANS; IMMUNOGLOBULIN G; PREDICTIVE VALUE OF TESTS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954620125     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.02.026     Document Type: Short Survey

References (60)

1. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602.
2. Marotte H., Pallot-Prades B., Grange L., et al. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and non-responders to infliximab. Arthritis Res Ther 2007, 9:R61.
3. Wolbink G.J., Voskuyl A.E., Lems W.F., et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:704-707.
4. Antoni C., Maini R.F.B. Subgroup analyses show consistent benefit in a 30-week double blind trial (Attract) with an anti-TNFα monoclonal antibody, infliximab, in rheumatoid arthritis patients on methotrexate. Ann Rheum Dis 1999, 58:217.
5. Hyrich K.L., Watson K.D., Silman A.J., et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45:1558-1565.
6. Kristensen L.E., Kapetanovic M.C., Gulfe A., et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008, 47:495-499.
7. Lequerre T., Jouen F., Brazier M., et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford) 2007, 46:446-453.
8. Buch M.H., Seto Y., Bingham S.J., et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of non-response and subsequent response to etanercept. Arthritis Rheum 2005, 52:42-48.
9. Bobbio-Pallavicini F., Caporali R., Alpini C., et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007, 66:302-307.
10. Braun-Moscovici Y., Markovits D., Zinder O., et al. Anticyclic citrullinated protein antibodies as a predictor of response to antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006, 33:497-500.
11. Potter C., Hyrich K.L., Tracey A., et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:69-74.
12. Schotte H., Schluter B., Willeke P., et al. Long-term treatment with etanercept significantly reduces the number of pro-inflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 2004, 43:960-964.
13. Drynda S., Kuhne C., Kekow J. Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis 2002, 61:254-256.
14. Chopin F., Garnero P., le Henanff A., et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:353-357.
15. Marotte H., Gineyts E., Miossec P., et al. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis 2009, 68:1197-1200.
16. Cuchacovich M., Soto L., Edwardes M., et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 2006, 35:435-440.
17. Marotte H., Arnaud B., Diasparra J., et al. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2008, 58:1258-1263.
18. Sekiguchi N., Kawauchi S., Furuya T., et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 2008, 47:780-788.
19. Gonzalez-Alvaro I., Ortiz A.M., Tomero E.G., et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 2007, 66:1675-1678.
20. Marotte H., Maslinski W., Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 2005, 7:R149-R155.
21. Trocme C., Marotte H., Baillet A., et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1328-1333.
22. Fabre S., Dupuy A.M., Dossat N., et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008, 153:188-195.
23. Hueber W., Tomooka B.H., Batliwalla F., et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R76.
24. Smeets T.J., Kraan M.C., van Loon M.E., et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003, 48:2155-2162.
25. Wang L., Chen W.Z., Wu M.P. Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the plasma HDL inflammatory index. Cytokine 2009.
26. Lequerre T., Gauthier-Jauneau A.C., Bansard C., et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R105.
27. Koczan D., Drynda S., Hecker M., et al. Molecular discrimination of responders and non-responders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008, 10:R50.
28. Pachot A., Arnaud B., Marrote H., et al. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol 2007, 34:2158-2161.
29. Kawashima M., Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann Rheum Dis 2005, 64:415-418.
30. Toh M.L., Marotte H., Blond J.L., et al. Over-expression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in non-responders to infliximab treatment. Arthritis Rheum 2006, 54:2109-2118.
31. Marotte H., Pallot-Prades B., Grange L., et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006, 65:342-347.
32. Kazkaz L., Marotte H., Hamwi M., et al. Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope. Ann Rheum Dis 2007, 66:195-201.
33. Criswell L.A., Lum R.F., Turner K.N., et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004, 50:2750-2756.
34. Kang C.P., Lee K.W., Yoo D.H., et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:547-552.
35. Padyukov L., Lampa J., Heimburger M., et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003, 62:526-529.
36. Martinez A., Salido M., Bonilla G., et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004, 50:1077-1082.
37. Pinto J.A., Rego I., Rodriguez-Gomez M., et al. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J Rheumatol 2008, 35:177-178.
38. Miceli-Richard C., Comets E., Verstuyft C., et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008, 67:478-484.
39. Mugnier B., Balandraud N., Darque A., et al. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003, 48:1849-1852.
40. Maxwell J.R., Potter C., Hyrich K.L., et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008, 17:3532-3538.
41. Fonseca J.E., Carvalho T., Cruz M., et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005, 64:793-794.
42. Guis S., Balandraud N., Bouvenot J., et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007, 57:1426-1430.
43. Seitz M., Wirthmuller U., Moller B., et al. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007, 46:93-96.
44. Balog A., Klausz G., Gal J., et al. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 2004, 71:274-280.
45. Chatzikyriakidou A., Georgiou I., Voulgari P.V., et al. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford) 2007, 46:1034-1035.
46. Constantin A., Dieude P., Lauwers-Cances V., et al. Tumor necrosis factor receptor II gene polymorphism and severity of rheumatoid arthritis. Arthritis Rheum 2004, 50:742-747.
47. Fabris M., Tolusso B., Di Poi E., et al. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002, 29:1847-1850.
48. Rooryck C., Barnetche T., Richez C., et al. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 2008, 26:340-342.
49. Toonen E.J., Coenen M.J., Kievit W., et al. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis 2008, 67:1174-1177.
50. Canete J.D., Suarez B., Hernandez M.V., et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1547-1552.
51. Tutuncu Z., Kavanaugh A., Zvaifler N., et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005, 52:2693-2696.
52. Liu C., Batliwalla F., Li W., et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008, 14:575-581.
53. Nzeusseu Toukap A., Galant C., Theate I., et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007, 56:1579-1588.
54. Ulfgren A.K., Andersson U., Engstrom M., et al. Systemic antitumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000, 43:2391-2396.
55. Wijbrandts C.A., Dijkgraaf M.G., Kraan M.C., et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 2008, 67:1139-1144.
56. Buch M.H., Reece R.J., Quinn M.A., et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology (Oxford) 2008, 47:1469-1475.
57. Barrera P., Joosten L.A., den Broeder A.A., et al. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 2001, 60:660-669.
58. Lindberg J., af Klint E., Catrina A.I., et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 2006, 8:R179.
59. Badot V., Galant C., Nzeusseu Toukap A., et al. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R57.
60. van der Pouw Kraan T.C., Wijbrandts C.A., van Baarsen L.G., et al. Responsiveness to antitumour necrosis factor alpha therapy is related to pretreatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis 2008, 67:563-566.